Joseph J. Larosa - 08 Dec 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP General Counsel and Secret
Signature
/s/**Joseph LaRosa
Issuer symbol
REGN
Transactions as of
08 Dec 2021
Net transactions value
-$7,618,479
Form type
4
Filing time
10 Dec 2021, 16:30:57 UTC
Previous filing
24 Aug 2021
Next filing
14 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Award $0 +3,338 +25% $0.000000 16,520 08 Dec 2021 Direct F1
transaction REGN Common Stock Options Exercise $5,373,900 +30,000 +182% $179.13 46,520 09 Dec 2021 Direct
transaction REGN Common Stock Tax liability $12,992,379 -19,772 -43% $657.11 26,748 09 Dec 2021 Direct
holding REGN Common Stock 3,186 08 Dec 2021 2021 GRAT
holding REGN Common Stock 314 08 Dec 2021 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -30,000 -100% $0.000000* 0 09 Dec 2021 Common Stock 30,000 $179.13 Direct F2
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +14,253 $0.000000 14,253 08 Dec 2021 Common Stock 14,253 $644.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.